Could common diabetes drugs boost immunotherapy in Hard-to-Treat cancers?
NCT ID NCT04114136
First seen Apr 30, 2026 · Last updated Apr 30, 2026
Summary
This study is for people with advanced solid tumors like melanoma, lung, liver, or stomach cancer. It tests whether adding metformin or rosiglitazone (diabetes drugs) to standard immunotherapy (anti-PD-1) can improve the body's ability to fight cancer. Participants receive one of three treatments and have biopsies before and after starting therapy to see how the drugs affect the tumor. The goal is to find a better way to control these cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.